Bernardo-Faura, Marti
Rinas, Melanie
Wirbel, Jakob
Pertsovskaya, Inna
Pliaka, Vicky
Messinis, Dimitris E.
Vila, Gemma
Sakellaropoulos, Theodore
Faigle, Wolfgang
Stridh, Pernilla
Behrens, Janina R.
Olsson, Tomas
Martin, Roland
Paul, Friedemann
Alexopoulos, Leonidas G.
Villoslada, Pablo
Saez-Rodriguez, Julio http://orcid.org/0000-0002-8552-8976
Funding for this research was provided by:
European Union 7FP-Programme (CombiMS, grant No 305397)
European Sys4MS project (Horizon2020: Eracosysmed: ID-43)
European Research Council Advanced Gran (ERC 340733-HLA-DR15 in MS)
Swiss National Science Foundation and the Swiss MS Society (Clinical Research Priority Project - disease heterogeneity of MS (CRPPMS; UZH))
Ruprecht-Karls-Universität Heidelberg
Article History
Received: 2 May 2019
Accepted: 14 June 2021
First Online: 16 July 2021
Declarations
:
: Patients were invited to participate and included in the study by their neurologist in charge of medical care and included after signing the informed consent. All appropriate IRB approvals to use the data from the clinical studies and the EGCG trial were obtained from these IRB committees with the following committee reference numbers. University of Zurich: Approved by the Cantonal Ethics Board of the Canton of Zurich, EC-Nr. 2013-0001. Karolinska Institutet: Approved by Regionala etikprövningsnämnden i Stockholm: Stop MS II, EC-Nr. 2009/2107-31/2. IDIBAPS: Approved by Comite de Etica Medica Hospital Clinic Barcelona, EC-Nr: 2012-7662. Charité University Medicine Berlin: Approved by Ethikkommission des Landes Berlin am Landesamt für Gesundheit und Soziales, EC-Nr. 2006-006323-39. Readers can gain access to the EGCG trial data as described in the original publication [CitationRef removed] by contacting ExternalRef removed, as far as permitted according to data protection requirements and consent provided by the participants. The research conformed to the principles of the Helsinki Declaration.All animal handling was carried out in accordance with the European Council Directive (2010/63/EU) and the Spanish regulations for the procurement and care of experimental animals (1201 RD/2005, October 10). All the study protocols were approved by the Ethical Committee on Animal Research of the University of Barcelona.
: Not applicable.
: DEM is an employee of ProtATonce; TO has received honoraria for lectures and/or advisory boards as well as unrestricted multiple sclerosis research grants from Allmiral, Astrazeneca, Biogen, Genzyme, Merck, and Novartis; RM reports grants and personal compensation from Biogen, personal fees from Genzyme Sanofi Aventis, grants and personal fees from Novartis, and personal fees from Merck Serono, Roche, Neuway, and CellProtect, outside the submitted work; FP has received research grants and personal compensation for activities with Alexion, Bayer, Chugai, Novartis, Merck, Teva, Sanofi, Genzyme, Biogen, and MedImmune; LGA is the founder and hold stocks at ProtATonce; PV holds stocks and has received consultancy fees from Bionure Farma SL, Spiral Therapeutics Inc., Spire Bioventures Inc., Attune Neurosciences Inc., QMenta Inc., and Health Engineering SL; JSR declares funding from GSK and Sanofi and consultant fees from Travere Therapeutics. The other authors declare that they have no competing interests.